Kneat Com Stock Price, News & Analysis

Kneat.com (TSX: KSI, OTCQC: KSIOF) has secured a three-year Master Services Agreement with a major US-based clinical diagnostics manufacturer. The unnamed customer operates in over 40 countries with 14,000+ employees and is part of a larger life sciences organization employing more than 60,000 people. The agreement focuses on digitizing the customer's equipment validation process using Kneat's Gx platform. The client specializes in providing diagnostic solutions to hospitals, laboratories, and physicians' offices globally. This partnership aligns with the broader industry trend of life sciences companies transitioning from manual, paper-based validation processes to digital solutions for improved quality, compliance, and market efficiency.

Kneat (KSIOF) reported strong financial results for Q1 2025, with total revenue reaching $14.7 million, up 37% year-over-year. The company's SaaS revenue grew 42% to $13.8 million, while Annual Recurring Revenue (ARR) increased 51% to $63.5 million. Gross profit rose 38% to $10.9 million, maintaining a steady gross margin of 74%. The company showed significant improvement in profitability with EBITDA of $5.9 million compared to -$0.5 million in Q1 2024, and Adjusted EBITDA of $2.3 million versus $0.6 million. During Q1, Kneat announced several key developments, including a partnership with Capgemini and new client acquisitions in therapeutics, consumer products, and pharmaceuticals. The company also expanded its executive team, appointing a new Chief Innovation Officer and Chief Product Officer.

Kneat (TSX: KSI, OTC: KSIOF), a leader in validation and quality process digitization, announced key executive changes. Co-founder Kevin Fitzgerald will transition from Chief Product Officer to the newly created role of Chief Innovation Officer in early June, focusing on strategic vision and product innovation. He will not seek re-election to the Board of Directors. Donal O'Sullivan will join as the new Chief Product Officer, bringing over 25 years of software development leadership experience. O'Sullivan joins from My Compliance Office where he served as CPO, and previously held positions at PICO Ltd as Global Head of Analytics Product Management and at Corvil for 18 years in various product management roles.

Kneat, a leader in validation and quality process digitization, will release its Q1 2025 financial results on May 7, 2025, after TSX market close. The company has scheduled a conference call and Q&A session for sell-side analysts on May 8, 2025, at 09:00 ET (14:00 GMT).

Key details:

• Earnings Release Date: May 7, 2025 (post-market)
• Conference Call Date: May 8, 2025
• Time: 09:00 ET / 14:00 GMT
• Presenters: Eddie Ryan (CEO) and Hugh Kavanagh (CFO)

Investors can access the financial results through the Financial Information section on Kneat's website. A registration link is available for the live webcast of the analyst call.

Kneat (KSIOF) has secured a Services Agreement with a major European-based multinational generic pharmaceuticals manufacturer to digitalize its drawing management process. The unnamed client, with over 20,000 employees and operations in more than 100 countries, will initially implement Kneat's platform at its largest European manufacturing facility.

The drawing management system will support engineering and validation processes by digitalizing technical drawings, eliminating paper-based errors, maintaining revision traceability, and controlling access. The client has the potential to expand Kneat's usage to streamline all validation workflows across their operations.

Kneat reports strong performance metrics, including a 151% net revenue retention rate as of December 31, 2024, and a 97% customer satisfaction rate rating their support as 'very good' or 'excellent'. The company serves the majority of the top 20 largest life sciences companies globally.

Kneat (KSIOF) reported strong financial results for Q4 and full year 2024, with significant growth across key metrics. Total revenue reached $13.7 million in Q4 2024, up 40% year-over-year, while SaaS revenue grew 41% to $12.5 million.

The company achieved notable improvements in profitability, with Q4 2024 gross profit increasing 48% to $10.4 million and gross margin reaching 75%. Annual Recurring Revenue (ARR) grew 60% to $59.7 million, and the company maintained a strong Net Revenue Retention Rate of 151%.

Throughout 2024, Kneat added five large strategic customers and strengthened its partner program with additions like Körber and ALTEN Group. The company completed two equity financings, raising aggregate gross proceeds of $55.6 million. In early 2025, Kneat announced new partnerships, including with Capgemini, and secured additional customer wins in the specialty therapeutics and consumer products sectors.

Kneat (TSX: KSI) (OTC: KSIOF), a company specializing in digitizing and automating validation and quality processes, has announced it will release its Q4 and full-year 2024 financial results on February 26, 2025, after TSX market close.

The company will host a conference call and Q&A session for sell-side analysts via webcast on February 27, 2025, at 09:00 ET (14:00 GMT). CEO Eddie Ryan and CFO Hugh Kavanagh will lead the presentation. The financial results will be accessible through the Financial Information section of Kneat's Investors page on their website.

Kneat (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major multinational consumer food and drink producer to digitize its validation processes. The European-headquartered company will initially implement Kneat's solutions for Equipment and Computer System Validation within its health sciences division, which employs over 5,000 people.

The agreement allows for potential expansion of Kneat's services across all affiliate companies and business divisions. This partnership demonstrates Kneat's expanding reach beyond traditional life sciences into consumer products, particularly for companies requiring validation regulatory compliance. The digitization initiative aims to help companies mitigate risk and protect their established brands.

Kneat.com (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major global therapeutics company to digitize its validation processes. The unnamed European company employs over 20,000 people across 100+ countries and operates more than ten manufacturing sites globally.

The client company provides supplies for Life Sciences organizations, focusing on research, clinical trials, manufacturing, diagnosis, and treatment. They will initially implement Kneat Gx for commissioning, qualification, and validation of manufacturing equipment and facilities. The partnership represents continued momentum for Kneat in attracting global Life Sciences leaders to its platform.